Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING-1: Dose-ranging Dolutegravir in HIV-1
NCT00951015Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Jul 2009; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00951015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951015.